Literature DB >> 19659607

Heat shock protein 70-binding protein 1 is highly expressed in high-grade gliomas, interacts with multiple heat shock protein 70 family members, and specifically binds brain tumor cell surfaces.

Michael W Graner1, Deborah A Raynes, Darell D Bigner, Vince Guerriero.   

Abstract

Chaperone proteins and heat shock proteins (HSP) are essential components of cellular protein folding systems under normal conditions; their expression and activities are upregulated during stress. Chronically stressed tumors frequently exhibit high chaperone protein levels, exploiting their anti-apoptotic mechanisms and general proteome homeostasis amidst a background of genetic instability. Co-chaperones interact with chaperones as malleable regulatory components of protein folding activity and may represent a conduit for modification of chaperone activity to the detriment of the tumor. We have initially characterized one such co-chaperone, heat shock protein 70-binding protein (HspBP) 1 from human brain tumors, their xenografts grown in immune-compromised mice, and in syngeneic murine models in immune-competent mice. Immunohistochemical analyses show HspBP1 overexpression (with unusual subcellular localizations) in patient brain tumors relative to normal brain tissue. This holds true for the xenograft and syngeneic murine tumor models. In biochemical affinity chromatography assays, HspBP1 interacts with members of the HSP70 family from brain tumor lysates and from surface-derived samples, including HSP70, glucose regulated protein (GRP)75, GRP78, and HSP110. From normal brain lysates, only heat shock cognate (HSC)70, GRP75, and HSP110 bind to HspBP1. FACS analyses indicate that HspBP1 binds to brain tumor cell surfaces, possibly via HSP70 family members, and internalizes into cells. This has implications for HspBP1 biology as well as its utility as a tumor-targeting agent. Our results suggest that HspBP1 may play a role in tumor (dys)regulation of chaperone proteins, and that HspBP1 may have extracellular roles with therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19659607      PMCID: PMC3680099          DOI: 10.1111/j.1349-7006.2009.01269.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  55 in total

1.  HspBP1, an Hsp70 cochaperone, has two structural domains and is capable of altering the conformation of the Hsp70 ATPase domain.

Authors:  Catherine A McLellan; Deborah A Raynes; Vince Guerriero
Journal:  J Biol Chem       Date:  2003-03-21       Impact factor: 5.157

2.  Cooperative interaction of Hsp40 and TPR1 with Hsp70 reverses Hsp70-HspBp1 complex formation.

Authors:  Won-Kyung Oh; Jaewhan Song
Journal:  Mol Cells       Date:  2003-08-31       Impact factor: 5.034

3.  HspBP1, a homologue of the yeast Fes1 and Sls1 proteins, is an Hsc70 nucleotide exchange factor.

Authors:  Mehdi Kabani; Catherine McLellan; Deborah A Raynes; Vince Guerriero; Jeffrey L Brodsky
Journal:  FEBS Lett       Date:  2002-11-06       Impact factor: 4.124

4.  Expression and functional activity of heat shock proteins in human glioblastoma multiforme.

Authors:  M Hermisson; H Strik; J Rieger; J Dichgans; R Meyermann; M Weller
Journal:  Neurology       Date:  2000-03-28       Impact factor: 9.910

5.  Identification of heat shock protein 60 as a molecular mediator of alpha 3 beta 1 integrin activation.

Authors:  Heba O Barazi; Longen Zhou; Nancy Smyth Templeton; Henry C Krutzsch; David D Roberts
Journal:  Cancer Res       Date:  2002-03-01       Impact factor: 12.701

6.  Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice.

Authors:  L He; H Feng; A Raymond; M Kreeger; Y Zeng; M Graner; L Whitesell; E Katsanis
Journal:  Cancer Immunol Immunother       Date:  2001-03       Impact factor: 6.968

7.  Positively charged templates for labeling internalizing antibodies: comparison of N-succinimidyl 5-iodo-3-pyridinecarboxylate and the D-amino acid peptide KRYRR.

Authors:  C F Foulon; P C Welsh; D D Bigner; M R Zalutsky
Journal:  Nucl Med Biol       Date:  2001-10       Impact factor: 2.408

Review 8.  EGFRvIII as a promising target for antibody-based brain tumor therapy.

Authors:  C T Kuan; C J Wikstrand; D D Bigner
Journal:  Brain Tumor Pathol       Date:  2000       Impact factor: 3.298

9.  Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers.

Authors:  Michael W Graner; Yi Zeng; Hanping Feng; Emmanuel Katsanis
Journal:  Cancer Immunol Immunother       Date:  2003-02-18       Impact factor: 6.968

10.  Proteomic and immunologic analyses of brain tumor exosomes.

Authors:  Michael W Graner; Oscar Alzate; Angelika M Dechkovskaia; Jack D Keene; John H Sampson; Duane A Mitchell; Darell D Bigner
Journal:  FASEB J       Date:  2008-12-24       Impact factor: 5.191

View more
  22 in total

Review 1.  Heat shock proteins as biomarkers for the rapid detection of brain and spinal cord ischemia: a review and comparison to other methods of detection in thoracic aneurysm repair.

Authors:  James G Hecker; Michael McGarvey
Journal:  Cell Stress Chaperones       Date:  2010-08-30       Impact factor: 3.667

2.  The unfolded protein response in glioblastomas: passing the stress test.

Authors:  Michael W Graner
Journal:  CNS Oncol       Date:  2013-11

3.  Targeting GRP78 to enhance melanoma cell death.

Authors:  Shaun Martin; David S Hill; James C Paton; Adrienne W Paton; Mark A Birch-Machin; Penny E Lovat; Chris P F Redfern
Journal:  Pigment Cell Melanoma Res       Date:  2010-07-12       Impact factor: 4.693

4.  Identification of potential tumor differentiation factor (TDF) receptor from steroid-responsive and steroid-resistant breast cancer cells.

Authors:  Izabela Sokolowska; Alisa G Woods; Mary Ann Gawinowicz; Urmi Roy; Costel C Darie
Journal:  J Biol Chem       Date:  2011-11-30       Impact factor: 5.157

5.  Neuron specific metabolic adaptations following multi-day exposures to oxygen glucose deprivation.

Authors:  Stephanie L H Zeiger; Jennifer R McKenzie; Jeannette N Stankowski; Jacob A Martin; David E Cliffel; BethAnn McLaughlin
Journal:  Biochim Biophys Acta       Date:  2010-07-23

Review 6.  Characterization of tumor differentiation factor (TDF) and its receptor (TDF-R).

Authors:  Izabela Sokolowska; Alisa G Woods; Mary Ann Gawinowicz; Urmi Roy; Costel C Darie
Journal:  Cell Mol Life Sci       Date:  2012-10-18       Impact factor: 9.261

7.  Investigation into the potential for hypoxic interior of neoplasms to enhance HSPA expression in glioma.

Authors:  Glenda M Beaman; David A Phoenix; Sarah R Dennison; Lee K Chatfield
Journal:  Mol Cell Biochem       Date:  2014-05-16       Impact factor: 3.396

8.  Reliability of HSP70 (HSPA) expression as a prognostic marker in glioma.

Authors:  Glenda Maria Beaman; Sarah R Dennison; Lee K Chatfield; David A Phoenix
Journal:  Mol Cell Biochem       Date:  2014-05-16       Impact factor: 3.396

Review 9.  Immunotherapy of brain cancers: the past, the present, and future directions.

Authors:  Lisheng Ge; Neil Hoa; Daniela A Bota; Josephine Natividad; Andrew Howat; Martin R Jadus
Journal:  Clin Dev Immunol       Date:  2011-03-08

10.  Medulloblastoma exosome proteomics yield functional roles for extracellular vesicles.

Authors:  Laura M Epple; Steve G Griffiths; Anjelika M Dechkovskaia; Nathaniel L Dusto; Jason White; Rodney J Ouellette; Thomas J Anchordoquy; Lynne T Bemis; Michael W Graner
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.